News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
259,831 Results
Type
Article (13534)
Company Profile (110)
Press Release (246187)
Section
Business (87898)
Career Advice (460)
Deals (15322)
Drug Delivery (63)
Drug Development (36507)
Employer Resources (49)
FDA (6252)
Job Trends (6181)
News (149910)
Policy (14002)
Tag
Academia (435)
Alliances (23066)
Alzheimer's disease (336)
Approvals (6240)
Artificial intelligence (47)
Bankruptcy (143)
Best Places to Work (4254)
Biosimilars (34)
Biotechnology (44)
Breast cancer (30)
Cancer (220)
Career advice (402)
Cell therapy (33)
Clinical research (30187)
Collaboration (94)
Compensation (48)
COVID-19 (744)
Data (188)
Diabetes (39)
Diagnostics (1217)
Drug pricing (53)
Earnings (31188)
Employer resources (43)
Events (36430)
Executive appointments (128)
FDA (6373)
Funding (73)
Gene therapy (50)
GLP-1 (277)
Government (1258)
Healthcare (3513)
Infectious disease (754)
Inflammatory bowel disease (45)
Interviews (57)
IPO (5793)
Job creations (2047)
Job search strategy (371)
Layoffs (166)
Legal (3404)
Lung cancer (40)
Manufacturing (67)
Medical device (1256)
Medtech (1258)
Mergers & acquisitions (9512)
Metabolic disorders (131)
Neuroscience (412)
NextGen Class of 2024 (1578)
Non-profit (589)
Northern California (312)
Obesity (83)
Opinion (107)
Patents (47)
People (28337)
Pharmaceutical (64)
Phase I (7848)
Phase II (12756)
Phase III (11473)
Pipeline (71)
Podcasts (37)
Policy (40)
Postmarket research (1399)
Preclinical (3141)
Radiopharmaceuticals (115)
Rare diseases (63)
Real estate (2627)
Regulatory (9755)
Research institute (562)
Resumes & cover letters (55)
Southern California (328)
Startups (1624)
United States (3234)
Vaccines (102)
Weight loss (67)
Date
Today (45)
Last 7 days (173)
Last 30 days (912)
Last 365 days (13038)
2024 (10186)
2023 (14244)
2022 (19556)
2021 (20068)
2020 (19034)
2019 (14887)
2018 (11713)
2017 (13890)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11923)
2010 (10888)
Location
Africa (312)
Arizona (36)
Asia (19694)
Australia (2541)
California (735)
Canada (508)
China (82)
Colorado (28)
Connecticut (33)
Europe (38568)
Florida (103)
Illinois (84)
Indiana (70)
Kansas (50)
Maryland (111)
Massachusetts (649)
Minnesota (46)
New Jersey (305)
New York (210)
North Carolina (247)
Northern California (312)
Ohio (35)
Pennsylvania (223)
South America (498)
Southern California (328)
Texas (104)
Washington State (57)
259,831 Results for "cantex pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER
Cantex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex’ azeliragon, a well-tolerated once-a-day pill, for the treatment of pancreatic cancer.
May 20, 2024
·
3 min read
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
Cantex Pharmaceuticals, Inc. announced today that Cantex’s azeliragon, a well-tolerated once-a-day pill that inhibits “RAGE” (the receptor for advanced glycation end products), will be featured in four abstracts at this year’s 2024 ASCO Annual Meeting to be held in Chicago.
May 28, 2024
·
3 min read
BioMidwest
Cantex Pharmaceuticals to Participate in the Bio CEO & Investor Conference
Cantex Pharmaceuticals, Inc. announced that Stephen Marcus, M.D., Chief Executive Officer, will participate in the BIO CEO & Investor Conference being held February 26-27, 2024 in New York City.
February 22, 2024
·
2 min read
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
Cantex Pharmaceuticals , Inc. announced today that the Company’s CEO, Stephen Marcus, M.D., will be an expert speaker at 5th Annual Glioblastoma Drug Development Summit, which will be held March 26-28 at the Hilton Boston Logan Airport.
March 19, 2024
·
4 min read
Drug Development
Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Cantex Pharmaceuticals, Inc. announced today the initiation of a Phase 2 clinical trial to assess the safety and effectiveness of Cantex’s azeliragon combined with stereotactic radiosurgery in patients with brain metastases.
August 28, 2023
·
4 min read
BioMidwest
Cantex Pharmaceuticals to Present at the Medinvest Oncology Investor Conference in Boston
Cantex Pharmaceuticals, Inc. announced that it will present at the MedInvest Oncology Investor Conference being held June 21-22, 2023, in Boston, MA.
June 15, 2023
·
2 min read
Drug Development
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA
Cantex Pharmaceuticals, Inc. and Lenox Hill Hospital’s Department of Neurological Surgery announced the initiation of a Phase 2 study to assess the safety and effectiveness of azeliragon in combination with radiation therapy as a treatment for newly diagnosed unmethylated glioblastoma.
September 18, 2023
·
4 min read
Drug Development
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL
Cantex Pharmaceuticals, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled, multicenter, Phase 3 pivotal clinical trial.
September 27, 2023
·
4 min read
CANTEX PHARMACEUTICALS ANNOUNCES ISSUANCE OF A PATENT FOR AZELIRAGON AS A TREATMENT OF GLIOBLASTOMA
Cantex Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 11,648,235, titled “Treatment of Glioblastoma,” with claims to a method of treating glioblastoma with azeliragon.
May 16, 2023
·
2 min read
Drug Development
Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer
Cantex Pharmaceuticals, Inc. today announced the initiation of a Phase 1/2 study to assess the safety and efficacy of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.
September 26, 2023
·
5 min read
1 of 25,984
Next
